Consensus QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-19 pm EDT			5-day change	1st Jan Change
11.38 ^USD	+4.98%		+14.26%	-60.15%

May. 07	UBS Adjusts Price Target on QuidelOrtho to $12 From $17, Maintains Neutral Rating	MT
May. 07	Jefferies Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $12.50 From $35	MT

Evolution of the Average Target: QuidelOrtho Corporation

Evolution of the Target Price: QuidelOrtho Corporation

Changes in Analyst Recommendations: QuidelOrtho Corporation

ada24a.hZ8K_h2YSFZ5NTwDU61h5Ukbm8pU2ESuEGS1KgQ3iZ8.1_FLhFu1EWUcAU5XBP8Ujnxh144yswqXWRGAGU105qzPqTuTVPdlYSYMXw~a9da85008dffcaadaf03b2f2fe8178f6

Analysts' recommendations: QuidelOrtho Corporation

May. 07	UBS Adjusts Price Target on QuidelOrtho to $12 From $17, Maintains Neutral Rating	MT
May. 07	Jefferies Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $12.50 From $35	MT
Apr. 10	UBS Adjusts Price Target on QuidelOrtho to $17 From $30, Maintains Neutral Rating	MT
Feb. 12	UBS Adjusts QuidelOrtho Price Target to $30 From $35, Maintains Neutral Rating	MT
Jan. 21	UBS Adjusts QuidelOrtho Price Target to $35 From $31, Maintains Neutral Rating	MT
Nov. 06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
Nov. 03	QuidelOrtho Receives FDA 510(k) Clearance for VITROS?? Immunodiagnostic Products hs Troponin I Assay	CI
Nov. 03	Quidelortho receives FDA 510(k) clearance for VITROS Immunodiagnostic Products hs Troponin I assay	RE
25-10-07	Citigroup Downgrades QuidelOrtho to Neutral From Buy, Adjusts Price Target to $33 From $40	MT
25-09-03	RBC Raises Price Target on QuidelOrtho to $62 From $60, Keeps Outperform Rating	MT
25-08-07	UBS Cuts Price Target on QuidelOrtho to $26 From $29, Maintains Neutral Rating	MT
25-05-08	UBS Cuts Price Target on QuidelOrtho to $29 From $45, Keeps Neutral Rating	MT
25-02-13	UBS Raises Price Target on QuidelOrtho to $45 From $43, Maintains Neutral Rating	MT
25-02-13	RBC Trims Price Target on QuidelOrtho to $61 From $64, Keeps Outperform Rating	MT
24-12-11	Citigroup Upgrades QuidelOrtho to Buy From Neutral, Raises Price Target to $50 From $44	MT
24-12-10	Jefferies Initiates QuidelOrtho at Hold With $43 Price Target	MT
24-11-08	UBS Cuts Price Target on QuidelOrtho to $43 From $50, Maintains Neutral Rating	MT
24-11-08	RBC Capital Adjusts QuidelOrtho Price Target to $64 From $62, Maintains Outperform Rating	MT
24-09-19	UBS Upgrades QuidelOrtho to Neutral From Sell, Adjusts Price Target to $50 From $42	MT
24-09-13	RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating	MT
24-09-05	QuidelOrtho Shares Rise After Craig-Hallum Upgrade	MT
24-09-05	Craig-Hallum Upgrades QuidelOrtho to Buy From Hold, Adjusts Price Target to $57 From $40	MT
24-06-24	RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating	MT
24-05-09	RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating	MT
24-03-04	UBS Downgrades QuidelOrtho to Sell From Neutral, Adjusts Price Target to $42 From $70	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
QUIDELORTHO CORPORATION			+71.82%
SARTORIUS AG			+22.36%
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	-	-	+23.5%
ECKERT & ZIEGLER SE			+54.29%
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.			+63.99%
REVENIO GROUP OYJ			+30.06%
VAREX IMAGING CORPORATION			+93.81%
CELLAVISION AB			+45.77%
Average			+50.70%
Weighted average by Cap.			+28.87%